Monthly Archives: October 2021

Immunology

OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy – Business Wire

SOUTHLAKE, Texas--(BUSINESS WIRE)--OncoNano Medicine, Inc. today announced a poster presentation at The American Association for Cancer Research (AACR) Virtual Conference on Tumor Immunology and Immunotherapy to be held on October 5-6, 2021.

Full details of the presentation are listed below:

TITLE: ONM-501 A Synthetic Polyvalent STING Agonist for Cancer Immunotherapy

PRESENTER: Qintai Su, Ph.D.DATE: October 5-6, 2021LOCATION: Virtual

The development of ONM-501 represents a new concept in STING activation that could overcome the challenges observed with earlier STING agonists. ONM-501 encapsulates the endogenous STING agonist cGAMP with a proprietary micelle that induces polyvalent STING condensation and prolongs innate immune activation to offer dual burst and sustained STING activation for a potential highly effective immunotherapy against cancer.

About OncoNano Medicine

OncoNano Medicine is developing a new class of products that utilize principles of molecular cooperativity in their design to exploit pH as a biomarker to diagnose and treat cancer with high specificity. Our product candidates and interventions are designed to help patients across the continuum of cancer care and include solid tumor therapeutics, agents for real-time image-guided surgery and a platform of immune-oncology therapeutics that activate and guide the bodys immune system to target cancer.

OncoNanos lead development candidate is pegsitacianine, a novel fluorescent nanoprobe, that is currently under study in Phase 2 clinical trials as a real-time surgical imaging agent for use in multiple cancer surgeries. ONM-501, OncoNanos second development program, is a next generation STING (STimulator of INterferon Genes) agonist that is advancing towards a first in human trial in the first half of 2023. Pegsitacianine and ONM-501 have been supported by grants received from the Cancer Prevention Research Institute of Texas. Learn more at http://www.OncoNano.com.

Originally posted here:
OncoNano Medicine to Present at The American Association for Cancer Research Virtual Conference on Tumor Immunology and Immunotherapy - Business Wire

Immunology

U of T research may help explain children’s immune response to COVID-19 – News@UofT

Researchers at the University of Toronto have found that immune cells from the upper respiratory tracts of children, taken years before the pandemic began, react with the virus that causes COVID-19.

The findings hint at a possible reason why children with COVID-19 are often asymptomatic or have mild symptoms, while many adults experience severe disease and even death.

We isolated B cells from tonsil tissues collected from children over five years ago, and found that some are reactive to the SARS-CoV-2 spike protein, saidGoetz Ehrhardt, principal investigator on the study and an associate professor ofimmunologyat U of TsTemerty Faculty of Medicine.

We found that antibodies generated from these B cells have neutralizing potential against the virus in lab experiments, reducing the ability of the spike protein to bind to its target protein on the cell surface.

The study,published in theJournal of Immunology, is one of just a few to examine the role of the mucosal immune system in COVID-19. Other studies have looked at immune components in the bloodoften after infection has taken hold or during recovery.

Mucosal surfaces comprise one of the largest components of the immune systemand include the gut, urogenital tract and respiratory system all of which teem with microbiota including bacteria, viruses and fungi.

The researchers at first assumed the B cells reacted to SARS-CoV-2 because they had encountered similar coronaviruses in the past, perhaps through common colds and other infections.

But the antibodies did not react to those coronaviruses in further testing, although they did share genetic sequence characteristics linked to other triggers.

Taken together, Ehrhardt said, the results suggest cross-reactivity in the B-cell antibodies. The immune system makes these antibodies toward certain agents or pathogensand as a by-product the antibodies react to SARS-CoV-2, he said. It will be interesting to find out what causes that reaction.

A better understanding of the antibody reaction could shed light on the mystery of COVID-19 susceptibility in children and adultsand inform clinical and public health decisions as well as therapeutic approaches.

Whatever the cause of the reaction, it is likely due to a common element in the childhood environment sinceall samples the researchers tested had the SARS-CoV-2-reactive B cells many of which were observed also in the immune systems naive or newly generated B cells that had not encountered any pathogen.

One explanation is that some of these B cells react to triggers in the microbiome, saidYanling Liu, lead author on the paper and a senior research associate in Ehrhardts lab.

Or it could still be that antibodies are reacting to endemic coronavirusesand we just didnt see that, Liu said. We dont really know, but one implication of our work is that it suggests children should respond to vaccines very well since they have those naive B cells ready to recognize vaccine in their lymphoid tissue.

Several other researchers were key to the study, Liu and Ehrhardt said, includingJames Rini, a professor ofbiochemistryandmolecular geneticsat U of T who provided purified spike proteins from viral samples.

Amin Ziaused computational biology to scan large databases and predict which antibodies would react to the virus. Zia was a post-doctoral researcherin the lab ofAlan Moses, a professor in U of Ts departments ofcell and systems biology,ecology and evolutionary biologyandcomputer science in the Faculty of Arts & Science.

About half the antibodies we generated were based on computer-generated predictions, said Ehrhardt. That was first for us, and it wont be a last.

Researchers atthe Hospital for Sick Children, with whom Ehrhardts lab has collaborated for years, supplied the tonsil tissue samples.

Mucosae are no doubt a very important interface for the immune systems response to a great variety of pathogens, but availability of samples has been a major impediment, said Ehrhardt. Research in this area is gathering steam, and it will be interesting to see where that takes us.

The research was funded by the Canadian Institutes of Health Research.

More:
U of T research may help explain children's immune response to COVID-19 - News@UofT

Immunology

Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer – StreetInsider.com

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

CAMBRIDGE, England--(BUSINESS WIRE)--Mogrify Limited (Mogrify), a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, today announced the appointment of Dr. Louise Modis as Chief Scientific Officer, following the recent completion of a $33 million USD Series A funding. Louise is an accomplished scientific leader in therapeutic discovery and development, and holds considerable experience in the progression of pre-clinical and clinical-stage assets, across various modalities and therapeutic areas. In her new role, Louise will lead the advancement of the Companys internal programs to help address high unmet clinical need in ophthalmology, immuno-oncology and other disease areas.

Louise has over 20 years experience in pre-clinical and clinical therapeutic research. Formerly Vice President of Immunology Research at GlaxoSmithKline (GSK), she led the generation and advancement of a pipeline of assets from target identification through to clinical proof-of-concept studies. Her roles at GSK included sponsorship of the Immunology Network, hosting external collaborators at GSK on sabbatical to nucleate and develop novel therapeutic concepts, championing in-licensing of assets, and representing GSK on the board of Sitryx. Prior to GSK, Louise led research teams at Boehringer Ingelheim Pharmaceuticals, and Millennium Pharmaceuticals (now Takeda), where she progressed therapeutic candidates targeted at immunology, oncology, and cardiovascular indications with unmet need. Dr. Modis holds a BSc (Biotechnology) from the National University of Ireland, Galway, earned her PhD (Developmental Hematology) at EMBL, Heidelberg, Germany and completed her postdoctoral fellowship at Harvard University, Boston.

Dr. Darrin M. Disley, OBE, CEO, Mogrify, said: We are delighted to welcome Louise to the Mogrify Executive Team following a global search that considered drug discovery specialists from across Europe and the United States. Louises domain expertise, intellectual curiosity and passion for developing novel modalities capable of transforming clinical outcomes for patients suffering with degenerative diseases, make her an ideal fit to lead our internal programs through to first-in-human studies.

Dr. Louise Modis, Chief Scientific Officer, Mogrify, added: I am very excited to join Mogrify and to be able to deploy its powerful cell reprogramming platform to address the most immediate challenges of developing cost-effective ex vivo cell therapies in immuno-oncology. I am particularly enthused by the Companys development of novel in vivo therapeutic modalities and the opportunity to progress a number of in vivo reprogramming therapies rapidly through development into the clinic.

For further information about Mogrifys team, please visit:

https://mogrify.co.uk/team/leadership-team/

View source version on businesswire.com: https://www.businesswire.com/news/home/20211005005528/en/

Zyme CommunicationsMichelle Ricketts, PhDTel: +44 (0)7789 053 885Email: michelle.ricketts@zymecommunications.com

Source: Mogrify Limited

See the original post:
Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer - StreetInsider.com

Immunology

Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancers (SITC) 36th Anniversary Annual Meeting – Yahoo…

CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body, announced today three poster presentations at the Society for Immunotherapy of Cancer's 36th Anniversary Annual Meeting (SITC 2021), to be held both in Washington, D.C. at the Walter E. Washington Convention Center and virtually November 10-14, 2021.

Presentation Details:Title: A phase 1 trial of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, alone and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer Poster #: 438Presenter: Dr. Sara I. Pai, M.D., Ph.D., associate professor of surgery, Division of Gastrointestinal and Oncologic Surgery; Director, Translational Research in Head and Neck Cancer Massachusetts General Hospital, Boston MADate: Saturday, November 13, 2021, Poster Hall (Hall E) 7 a.m.8:30 p.m. EST

Title: CUE-102 selectively activates and expands WT1-specific T cells for the treatment of patients with WT1+ malignancies Poster #: 720Presenter: Dr. Christie Zhang, Ph.D., senior scientist, discovery and translational immunology, Cue Biopharma Date: Saturday, November 13, 2021, Poster Hall (Hall E) 7 a.m.8:30 p.m. EST

Title: Targeting engineered interleukin-2 (IL-2) to antigen specific T cells via novel biologic platformsPoster #: 793Presenter: Raymond J. Moniz, associate director, discovery and translational immunology, Cue BiopharmaDate: Friday, November 12, 2021, Poster Hall (Hall E) 7 a.m.8:30 p.m. EST

ePosters will be on display on the SITC 2021 virtual meeting platform from 7 a.m. EST on Friday, Nov. 12, 2021 until the virtual meeting platform is closed on Jan. 9, 2022.

We look forward to presenting additional preclinical and clinical data that continues to validate the therapeutic potential of our IL-2 based CUE-100 series Immuno-STAT platforms and biologics, said Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma. We believe the data demonstrated in these posters show great promise in selective and specific tumor targeting for the treatment of multiple cancers and other life-threatening diseases.

Story continues

About the CUE-100 SeriesThe CUE-100 series consists of Fc-fusion biologics that incorporate peptide-MHC (pMHC) molecules along with rationally engineered IL-2 molecules. This singular biologic is anticipated to selectively target, activate and expand a robust repertoire of tumor-specific T cells directly in the patient. The binding affinity of IL-2 for its receptor has been deliberately attenuated to achieve preferential selective activation of tumor-specific effector T cells while reducing potential for effects on regulatory T cells (Tregs) or broad systemic activation, potentially mitigating the dose-limiting toxicities associated with current IL-2-based therapies.

About SITCThe Society for Immunotherapy of Cancer (SITC) is the worlds leading member-driven organization specifically dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy.

SITC is a 501(c)(3) not-for-profit medical professional society of influential research scientists, physician scientists, clinicians, patients, patient advocates, government representatives and industry leaders dedicated to improving cancer patient outcomes by advancing the science and application of cancer immunotherapy. Through educational programs that foster scientific exchange and collaboration, SITC aims to one day make the word cure a reality for cancer patients everywhere.

Currently, SITC has more than 4,650 members who represent over 35 medical specialties in 63 countries around the world.

Through emphasis on high-caliber scientific meetings; dedication to education and outreach activities; focus on initiatives of major importance in the field; and commitment to collaborations with like-minded domestic and international organizations, government and regulatory agencies, associations and patient advocacy groups, SITC brings together all aspects of the cancer immunology and immunotherapy community.

About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is engineering a novel class of injectable biologics to selectively engage and modulate targeted T cells directly within the patients body to transform the treatment of cancer, infectious disease and autoimmune disease. The companys proprietary Immuno-STAT (Selective Targeting and Alteration of T cells) platform, is designed to harness the bodys intrinsic immune system without the need for ex vivo manipulation.

Headquartered in Cambridge, Massachusetts, the company is led by an experienced management team and independent Board of Directors with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics.

For more information, visit https://www.cuebiopharma.com and follow us on Twitter at https://twitter.com/CueBiopharma.

Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that are intended to be covered by the safe harbor created by those sections. Such forward-looking statements include, but are not limited to, those regarding: the companys estimate of the period in which it expects to have cash to fund its operations; the companys belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective engagement of disease-relevant T cells; and the companys business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the companys future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as believe, expect, may, will, should, would, could, seek, intend, plan, goal, project, estimate, anticipate, strategy, future, likely or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the companys strategies, prospects, financial condition, operations, costs, plans and objectives are forward-looking statements. Important factors that could cause the companys actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the companys limited operating history, limited cash and a history of losses; the companys ability to achieve profitability; potential setbacks in the companys research and development efforts including negative or inconclusive results from its preclinical studies, its ability to secure required U.S. Food and Drug Administration (FDA) or other governmental approvals for its product candidates and the breadth of any approved indication; adverse effects caused by public health pandemics, including COVID-19, including possible effects on the companys trials; negative or inconclusive results from the companys clinical trials or preclinical studies or serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the companys reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the companys ability to obtain adequate financing to fund its business operations in the future; operations and clinical the companys ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the companys most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.

Investor ContactGeorge B. Zavoico, Ph.D.VP, Investor Relations & Corporate Development Cue Biopharma, Inc. gzavoico@cuebio.com

Media ContactDarren Opland, Ph.D.LifeSci Communicationsdarren@lifescicomms.com

Originally posted here:
Cue Biopharma Announces Upcoming Scientific Presentations at the Society for Immunotherapy of Cancers (SITC) 36th Anniversary Annual Meeting - Yahoo...

Immunology

Cohort profile: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) – DocWire News

This article was originally published here

BMJ Open. 2021 Sep 30;11(9):e047133. doi: 10.1136/bmjopen-2020-047133.

ABSTRACT

PURPOSE: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) is a prospective cohort study in South Africa investigating the association between antiretroviral therapy (ART) use, preterm delivery (PTD) and small-for-gestational age (SGA) live births. PIMS main hypotheses are that ART initiation in pregnancy and ART-induced hypertension are associated with PTD and SGA respectively and that reconstitution of cellular immune responses in women on ART from before pregnancy results in increases in PTD of GA infants.

PARTICIPANTS: Pregnant women (n=3972) aged 18 years regardless of HIV status recruited from 2015 to 2016 into the overall PIMS cohort (2517 HIV-negative, 1455 living with HIV). A nested cohort contained 551 women living with HIV who were 24 weeks GA on ultrasound: 261 initiated ART before pregnancy, 290 initiated during the pregnancy.

FINDINGS TO DATE: Women in the overall cohort were followed antenatally through to delivery using routine clinical records; further women in the nested cohort were actively followed up until 12 months post partum, with data collected on maternal health (HIV care and ART use, clinical care and intercurrent clinical history). Other procedures conducted on the nested cohort included physical examinations (anthropometry, blood pressure measurement), assessment of fetal growth (ultrasound), maternal and infant phlebotomy for storage of plasma, RNA and peripheral blood mononuclear cells, collection of delivery specimens (placenta and cord blood) and infant 12-month developmental assessment. Preliminary findings have contributed to our understanding of risk factors for adverse birth outcomes, and the relationship between pregnancy immunology, HIV/ART and adverse birth outcomes.

FUTURE PLANS: Using specimens collected from study participants living with HIV throughout pregnancy and first year of life, the PIMS provides a valuable platform for answering a variety of research questions focused on temporal changes of immunology markers in women whose immune status is altered by HIV infection, and how ART initiated during the pregnancy affects immune responses. The relationship between these immunological changes with adverse birth outcomes as well as possible longer-term impact of exposure to ART in fetal and early life will be explored. Additionally, further active and passive follow-up of mothers and their infants is planned at school-going age and beyond to chart growth, morbidity and development, as well as changes in family circumstances.

PMID:34593488 | DOI:10.1136/bmjopen-2020-047133

Go here to read the rest:
Cohort profile: Prematurity Immunology in Mothers living with HIV and their infants Study (PIMS) - DocWire News

Immunology

1700+ Graduates from Class of 2020 Expected to Return for Long-awaited In-Person Commencement Ceremony – UCF

Homecoming weekend will mean a little bit more to a special group of 1,700 Knights expected to return to campus to experience the milestone of an in-person commencement. For some, this graduation ceremony has been delayed more than a year.

Spring, Summer and Fall 2020 grads representing each of UCFs 13 colleges have registered for the ceremony, which will take place Nov. 5 at 9 a.m. at Addition Financial Arena and be livestreamed on UCFs YouTube channel.

Darin Edwards 97 10MS 11PhD who led the charge to create Modernas mRNA COVID-19 vaccine will serve as the keynote speaker for the 2020 Graduation Celebration.

In 2020, the Florida Board of Governors required all of Floridas state universities to hold virtual commencement ceremonies due to the COVID-19 pandemic. UCF conferred more than 18,000 degrees during its 2020 virtual commencement ceremonies.

During the ceremony, graduates will cross the stage during the traditional Pomp and Circumstance processional as their names are called. Each graduate is allowed up to four guests in attendance.

The deadline to participate in the Nov. 5 ceremony has passed. Participation in the ceremony is specifically for those graduates who missed in-person commencements experiences in 2020. Other graduates who would like to participate in a make-up ceremony may walk during the fall commencement ceremonies, which will be held Dec. 17-18.

Edwards is the director of immunology in the infectious disease group at Moderna, where he led the research and development on their mRNA COVID-19 vaccine. Additionally, he directs the immunology team in support of vaccine development programs and foundational research efforts, and leads work with external academic and industry collaborators including Modernas collaborative research efforts with the National Institute of Health, WHO, and Harvards pathogenesis working group.

Prior to joining Moderna in June 2019, Edwards served eight years for Sanofi Pasteur in Orlando, where he worked to develop vaccines against infectious diseases, including RSV, influenza, dengue, and yellow fever.

Edwards is a much-published researcher and academic speaker.Through his educational background at UCF, combined with his yearsof experience working on the development of next-generation vaccinetechnology, he has had the unique opportunity to make adirect and positive impact on global health.

He earned a bachelors inbiology, a masters in molecularbiology and microbiology and a doctorate inbiomolecular sciences from UCF, where he was also a Burnett Honors Scholar.

The health and well-being of all UCF graduates and their guests are the top priority of the university. Face coverings are expected while indoors for all attendees whether vaccinated or not, in accordance withthe latest CDC guidelines.

Continue reading here:
1700+ Graduates from Class of 2020 Expected to Return for Long-awaited In-Person Commencement Ceremony - UCF

Immunology

U of M research: vaccine offers greater protections for those who’ve already had COVID – MinnPost

The Star Tribunes Jeremy Olson writes: New University of Minnesota research is contesting a key argument against COVID-19 vaccination that people with prior coronavirus infections dont need further immunization to protect themselves. Comparing blood samples following COVID-19 vaccinations in 48 participants, the U researchers found that everyone gained key memory B cells capable of producing antibodies that fight off the coronavirus, but people with previous infections gained five times more of those cells. And in the world of immunology, more is better, said Marc Jenkins, a co-author and director of the Center for Immunology at the U Medical School.

WCCO-TV reports: Violence Free Minnesota released its 2020 homicide report on Friday, which analyzes relationship abuse in the state. In all, the report says that at least 30 people were killed due to intimate partner violence in 2020, and all but one of the victims identified as a woman. Of the 30 victims, 21 were killed by a current or former intimate partner, and nine victims were friends or family members attempting to intervene. Three of the victims were children.

For MPR, Mat Sepic writes: The lawyers prosecuting Kimberly Potter, the former police officer who killed Daunte Wright, are planning to introduce evidence showing that Potter was trained in the proper use of a Taser. As Potter, 49, and another Brooklyn Center officer tried to arrest Wright on a firearms warrant during a traffic stop April 11, he broke free and got back in his car. Potter is heard on video shouting Taser but instead pulls her handgun and shoots Wright in the chest. Potter is charged with first and second-degree manslaughter.

At FOX 9, Howard Thompson reports: A man is in custody after a police chase turned into a standoff with shots fired in Duluth, Minnesota on Friday. In tweets Friday evening, police say the suspect, who officers say was wanted following an attempted bank robbery and police chase, surrendered at about 8:30 p.m., hours after the incident began. According to police, the incident started at about 12:30 p.m. with a pursuit through the city and surrounding areas.

Article continues after advertisement

For MPR, Jon Collins writes: A pilot program launching Monday is aimed at freeing up Minneapolis police by using civilian city employees to enforce parking violations overnight. Parking control officers have traditionally enforced parking regulations during daylight hours and then handed duties off to the Minneapolis police for the night. Saray Garnett-Hochuli, interim director for regulatory services, said complaints about parking violations during these hours often went unaddressed because they were a low priority for police.

In the Pioneer Press, Betsy Helfand writes: A season that began with playoff aspirations will officially end with a fifth-place finish for the Twins, their first time winding up in the American League Central cellar since 2016, when they finished with the worst record in the majors. With an 11-6 loss to Kansas City on Friday night at Kauffman Stadium, the Twins (71-89) are three games behind the Royals (74-86) with two to play, locking them into fifth place in 2021 after winning division titles in each of the past two seasons.

Stephen Groves writes for the AP: South Dakota Gov. Kristi Noem on Friday defended her administrations handling of her daughters application for a real estate appraiser license, attempting to brush aside questions about a meeting she held last year that included her daughter, Kassidy Peters, and the state employee who was overseeing her application. I never once asked for special treatment for Kassidy, the Republican governor said in video posted on YouTube days after The Associated Press first reported on the meeting. The meeting happened after the Department of Labor and Regulation moved to deny Peters the license. Four months later, in November 2020, Peters received her certification as a residential appraiser, according to the department.

Here is the original post:
U of M research: vaccine offers greater protections for those who've already had COVID - MinnPost

Immunology

‘Last throw of the dice’ for Covid-19, claims Professor Luke O’Neill – Dublin Live

A leading immunology expert has given hope that Covid-19 may finally be on its "last throw of the dice".

The Delta variant completely changed how the public lives with Covid-19 given its higher transmissibility compared to previous strains of the disease.

But Professor Luke O'Neill of Trinity College told Today with Claire Byrne this morning that Delta "may be as bad as it gets" with vaccines holding firm against it.

"The vaccine is holding firmly against Delta is the message," he said.

A new study shows protection from the Pfizer vaccination remains at 90% six months after the second dose is administered.

However, Professor O'Neill adopted a more cautious tone when it came to giving booster shots to the wider population.

Professor O'Neill said: "It may change when it gets to nine months out or 12 months, then that might be slightly different."

He added if there's evidence of increased risk in six months time "then you may start giving a booster - it may well become a three-shot vaccine finally".

To get the latest breaking news straight to your inbox, sign up for our free newsletter

Read more:
'Last throw of the dice' for Covid-19, claims Professor Luke O'Neill - Dublin Live

Immunology

Global Immunology Drug Market 2021 Industry Insights and Major Players are Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune…

Comprehensive Global Immunology Drug Market from 2021 to 2027 analysis with precise projections and predictions, as well as full research solutions for strategic decision-making, are provided by Market Research Place studies. It also has separate chapters that include the regional studies to get a picture of the markets with future opportunities followed by the estimated yearly growth during the survey period from 2021 to 2027.

The report investigates the market by examining market dynamics, market trends, current trends, issues, challenges, competition analysis, and the firms involved. The study also goes into great detail on supply and demand assessments, as well as the participation of major industry players and market share growth statistics. All of the income margins, pricing, revenue proportions, and gross margins are determined in part.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketresearchplace.com/report-detail/216577/request-sample

It examines the market segments in the Immunology Drug market in depth:

The study takes into account a diverse variety of manufacturers, with business profiles of included

It provides granular analysis of the market segments of the Immunology Drug market:

The evaluation covers the major geographical areas that the industry operates in, including

ACCESS FULL REPORT: https://www.marketresearchplace.com/report/global-immunology-drug-market-research-report-2021-2027-216577.html

Main Points of the Report

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team (sales@marketresearchplace.com), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: sales@marketresearchplace.com

Read the rest here:
Global Immunology Drug Market 2021 Industry Insights and Major Players are Abbott Laboratories, Active Biotech, Eli Lilly and Company, Autoimmune...

Immunology

AbbVie to Host Third-Quarter 2021 Earnings Conference Call – WITN

Published: Oct. 5, 2021 at 8:00 AM EDT|Updated: 7 hours ago

NORTH CHICAGO, Ill., Oct. 5, 2021 /PRNewswire/ --AbbVie (NYSE: ABBV) will announce its third-quarter 2021 financial results on Friday, October 29, 2021, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. Central time. It will be accessible through AbbVie's Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvieon Twitter, Facebook, Instagram, YouTubeand LinkedIn.

View original content:

SOURCE AbbVie

The above press release was provided courtesy of PRNewswire. The views, opinions and statements in the press release are not endorsed by Gray Media Group nor do they necessarily state or reflect those of Gray Media Group, Inc.

Go here to read the rest:
AbbVie to Host Third-Quarter 2021 Earnings Conference Call - WITN